Form 4: Dogwood Therapeutics: Major Preferred Stock Conversion

Dogwood Therapeutics' Series A and A-1 Preferred Stock held by Sealbond and Conjoint converted into common shares, significantly altering beneficial ownership and board representation.

Summary

• On November 21, 2025, Dogwood Therapeutics, Inc. completed the conversion of its Series A Non-Voting Convertible Preferred Stock and Series A-1 Non-Voting Convertible Preferred Stock into shares of Common Stock, following stockholder approval.
• Sealbond Ltd converted 2,161.095 shares of Series A Preferred Stock into 21,610,950 shares of Common Stock.
• Conjoint Inc. converted 284.2638 shares of Series A-1 Preferred Stock into 2,842,638 shares of Common Stock.
• Each share of Preferred Stock automatically converted into 10,000 shares of Common Stock.
• Following these transactions, Sealbond Ltd directly beneficially owns 21,822,333 shares of Common Stock.
• Conjoint Inc. indirectly beneficially owns 2,842,638 shares of Common Stock.
• Mr. Yu Ying Choi Alan Abel and Dr. Toh Kean Meng Melvin, executives of CK Life Sciences Int'l., (Holdings) Inc., have been appointed to the board of directors of Dogwood Therapeutics, Inc., representing the reporting persons.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The conversion simplifies the capital structure and increases the common stock holdings of significant investors, potentially aligning interests. The appointment of directors from a major shareholder also suggests increased strategic involvement.

Positives

• The conversion simplifies the capital structure by reducing the number of preferred stock classes and increasing the common stock float.
• Increased common stock holdings by significant investors (Sealbond and Conjoint, subsidiaries of CK Life Sciences Int'l., (Holdings) Inc.) may indicate stronger alignment of interests with common shareholders.
• The appointment of two executives from a major shareholder (CK Life Sciences Int'l., (Holdings) Inc.) to the board of directors could bring strategic oversight and expertise.

Future Outlook

This Form 4 filing reports a completed transaction and does not contain explicit forward-looking statements or guidance regarding future financial performance or strategic direction.

Industry Context

This filing details a specific corporate action by Dogwood Therapeutics, Inc. and its major shareholders, rather than reflecting broader industry trends. The conversion of preferred stock to common stock is a common event in a company's lifecycle, often aimed at simplifying its capital structure.

Management Changes

Corporate Governance

Related Party Transactions

• The conversion of Preferred Stock into Common Stock involves Sealbond Ltd and Conjoint Inc., which are subsidiaries of CK Life Sciences Int'l., (Holdings) Inc., a significant shareholder and reporting person for Dogwood Therapeutics, Inc.

Stakeholder Impact

• Shareholders: The conversion increases the number of outstanding common shares, potentially impacting per-share metrics. It also increases the beneficial ownership and influence of CK Life Sciences Int'l., (Holdings) Inc. through its subsidiaries and board representatives.
• Employees: No direct impact on employees is indicated in this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated in this filing.

Key Dates

Keywords

Dogwood Therapeutics, DWTX, SEC Form 4, Beneficial Ownership, Stock Conversion, Preferred Stock, Common Stock, Sealbond Ltd, Conjoint Inc., CK Life Sciences, Corporate Governance, Director Appointment